

**Revised Draft Agenda**  
**Biocides Working Group Meeting III-2017**

**29 May – 2 June 2017**

ECHA Conference Centre (Annankatu 18, Helsinki)  
 Meeting room Margot Wallstrom (MW)  
 Meeting room K325  
 Meeting room Marie Curie (MC)

Coffee break 11:00-11:30  
 Lunch break 13:00-14:00  
 Coffee break 15:30-16:00

Monday 29 May	09:00-13:00	APCP WG (K325)
	14:00-18:00	
Tuesday 30 May	09:00-13:00	APCP WG (K325)
	14:00-17:00	
Tuesday 30 May	09:30-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 31 May	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Thursday 1 June	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 31 May	09:30-13:00	EFF WG (K325)
	14:00-18:00	
Thursday 1 June	09:00-13:00	EFF WG (K325)
	14:00-16:30	
Tuesday 30 May	09:00-13:00	2 <sup>nd</sup> PT 18 EG meeting (MC) (only for assigned experts)
	14:00-17:00	
Wednesday 31 May	09:30-13:00	ENV WG (MC)
	14:00-18:00	
Thursday 1 June	09:00-13:00	ENV WG (MC)
	14:00-18:00	
Friday 2 June	09:00-13:00	ENV WG (MC)

## **Analytical methods and physico-chemical properties Working Group**

**Chair: Bernhard Krebs**

### **Item 1 – Welcome and apologies**

### **Item 2 – Administrative issues**

### **Item 3 – Agreement of the agenda**

*For agreement*

### **Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

### **Item 5 – Agreement of the draft minutes from WG-II-2017**

Meeting documents:

- *WG II 2017\_APCP\_7-1\_draft minutes*
- *WG II 2017\_APCP\_7-2\_draft minutes*
- *WG II 2017\_APCP\_7-3\_draft minutes*
- *WG II 2017\_APCP\_gen agenda items\_draft minutes\_updated*

*For agreement*

### **Item 6 – Follow-ups of previous WG meetings**

#### **6.1 Follow-up of previous working group meetings**

### **Item 7 – Technical and scientific issues and e-consultations**

#### **7.1 Redefinition of polymeric betain**

Meeting document: *WG III 2017\_APCP\_7-1*

*For discussion/agreement*

#### **7.2 Ethanol outcome of the e-consultation**

Meeting document: *WG III 2017\_APCP\_7-2*

*For discussion/agreement*

#### **7.3 Substance identification of silver substances**

Meeting document: *WG III 2017\_APCP\_7-3*

*For discussion/agreement*

#### **7.4 Biocidal Product Families**

Meeting document: *WG III 2017\_APCP\_7-4*

*For discussion/agreement*

- 7.5 Carbon dioxide generated in situ outcome of the e-consultation**  
Meeting document: *WG III 2017\_APCP\_7-5*  
*For discussion/agreement*
- 7.6 Prallethrin outcome of the e-consultation**  
Previous meeting: *WG II 2014*  
Meeting document: *WG III 2017\_APCP\_7-6*  
*For discussion/agreement*
- 7.7 Guidance on in situ generated active substances**  
Previous meeting: *WG V 2016*  
Meeting document: *WG III 2017\_APCP\_7-7*  
*For discussion/agreement*
- 7.8 Use of literature**  
Meeting document: *WG III 2017\_APCP\_7-8*  
*For discussion/agreement*
- 7.9 Definitions used and applied**  
Meeting document: *WG III 2017\_APCP\_7-9*  
*For discussion/agreement*
- 7.10 Naming of active substances (provisional)**  
Meeting document: *WG III 2017\_APCP\_7-10*  
*For discussion/agreement*

## **Item 8 – Discussion on Union authorisations**

- 8.1 Early WG discussion on UA applications for product families containing Iodine/PVP-Iodine**  
Meeting document: *WG III 2017\_APCP\_8-1*  
*For discussion/agreement*

## **Item 9 – Discussion on active substances**

- 9.1 Azoxystrobin (eCA UK)**  
PT 07, 09, 10  
Meeting document: *WG III 2017\_APCP\_9-1*  
*For discussion/agreement*
- 9.2 d-Allethrin (eCA DE)**  
PT 18  
Meeting document: *WG III 2017\_APCP\_9-2*  
*For discussion/agreement*
- 9.3 Esbiothrin (eCA DE)**  
PT 18  
Meeting document: *WG III 2017\_APCP\_9-3*  
*For discussion/agreement*

**9.4 PHMB (1415; 4.7) (eCA FR)**

PT 01, 02, 04, 05, 06

Meeting document: *WG III 2017\_APCP\_9-4*

*For discussion/agreement*

**9.5 Chlorophene (eCA NO)**

PT 02, 03

Meeting document: *WG III 2017\_APCP\_9-5*

*For discussion/agreement*

**9.6 Peroxyoctanoic acid, early working group discussion (eCA FR)**

PT 02, 03, 04

Previous meeting: *WG II 2014*

Meeting document: *WG III 2017\_APCP\_9-6*

*For discussion/agreement*

**Item 10 – AOB**

## Human Health Working Group

Chair: Antero Airaksinen

### Item 1 – Welcome and apologies

### Item 2 – Administrative issues

### Item 3 – Agreement of the agenda

*For agreement*

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 – Agreement of the draft minutes from WG-II-2017

Meeting documents:

- WGII2017\_TOX\_6-1
- WGII2017\_TOX\_6-2
- WGII2017\_TOX\_6-3
- WGII2017\_TOX\_7-6
- WGII2017\_TOX\_Minutes\_draft.docx

*For agreement*

### Item 6 – Discussion of active substances

#### 6.1 Chlorophene (eCA NO)

PT 2, 3

Meeting document: WGIII2017\_TOX\_6-1

*For discussion/agreement*

#### 6.2 Azoxystrobin (eCA UK)

PT 7, 9, 10

Meeting document: WGIII2017\_TOX\_6-2

*For discussion/agreement*

#### 6.3 PHMB (1415; 4.7) (eCA FR)

PT 1, 2, 4, 5, 6

Meeting document: WGIII2017\_TOX\_6-3

*For discussion/agreement*

#### 6.4 d-Allethrin (eCA DE)

PT 18

Meeting document: WGIII2017\_TOX\_6-4

*For discussion/agreement*

#### 6.5 Esbiothrin (eCA DE)

PT 18

Meeting document: WGIII2017\_TOX\_6-5

*For discussion/agreement*

## Item 7 – Discussion of Union authorisations

### 7.1 Early WG discussion on UA applications for product families containing Iodine/PVP-Iodine – WebEx

Meeting document: *WGIII2017\_TOX\_7-1*

*For discussion/agreement*

## Item 8 – Technical and guidance related issues

### 8.1 Update on guidance development

SECR to inform

*For information*

#### (a) Update on Ad hoc Working Group - Human Exposure (HEAdhoc)

SECR to inform

*For information*

#### (b) Update on Ad hoc Working Group – Assessment of residue transfer to food (ARTFood)

SECR to inform

*For information*

### 8.2 Recommendations of HEAdhoc

#### (a) Default human factor values for use in exposure assessments for biocidal products (revision of HEEG Opinion 17)

Meeting documents: *WGIII2017\_TOX\_8-2* (documents a-e)

*For agreement*

#### (b) Proposal for harmonising the assessment of human exposure to repellents (PT 19) – (revision of HEAdhoc recommendation 11)

Meeting documents: *WGIII2017\_TOX\_8-2* (documents f-h)

*For agreement*

### 8.3 WG discussions on issues related to classification and labelling

Meeting document: *WGIII2017\_TOX\_8-3*

*For agreement*

### 8.4 Data requirements for precursors of *in situ* generated active substances

Meeting document: *WGIII2017\_TOX\_8-4*

*For agreement*

### 8.5 Product residues from paper used for food/feed packaging (PT 12)

Meeting document: *WGIII2017\_TOX\_8-5*

*For agreement*

### 8.6 Definition of relevant impurities

Meeting document: *WGIII2017\_TOX\_8-6*

*For discussion*

**8.7 Dermal absorption of anticoagulant rodenticides**

Meeting document: WGIII2017\_TOX\_8-7

*For discussion/agreement*

**Item 9 – AOB**

**9.1 Update on Union Authorisation**

SECR to inform

*For information*

**9.2 Assessment of Endocrine Disruptors – update on status**

SECR to inform

*For information*

**9.3 Other information & lessons learned**

SECR/WG members to inform and to reflect on the experience gained

*For information*

**Efficacy Working Group**  
**Chair: Katarzyna Szymankiewicz**

**Item 1 – Welcome and apologies**

**Item 2 – Administrative issues**

**Item 3 – Agreement of the agenda**

*For agreement*

**Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

**Item 5 – Agreement of the draft minutes from WG-II-2017**

Meeting documents:

- WGII2017\_EFF\_6-1\_draft\_minutes.docx
- WGII2017\_EFF\_6-2\_draft\_minutes.docx
- WGII2017\_EFF\_draft\_minutes.docx

*For agreement*

**Item 6 – Discussion of active substances**

**6.1 Chlorophene (eCA NO)**

PT 02, 03

Meeting document: WGIII2017\_EFF\_6-1

*For discussion/agreement*

**6.2 Azoxystrobin (eCA UK)**

PT 07, 09, 10

Meeting document: WGIII2017\_EFF\_6-2

*For discussion/agreement*

**6.3 d-Allethrin (eCA DE)**

PT 18

Meeting document: WGIII2017\_EFF\_6-3

*For discussion/agreement*

**6.4 Esbiothrin (eCA DE)**

PT 18

Meeting document: WGIII2017\_EFF\_6-4

*For discussion/agreement*

**6.5 PHMB (1415; 4.7) (eCA FR)**

PT 01,02,04,05,06

Meeting document: WGIII2017\_EFF\_6-5

*For discussion/agreement*



**6.6 Cyphenothrin (eCA EL)**

PT 18

Meeting document: *WGIII2017\_EFF\_6-6*

*For discussion/agreement*

**6.7 Copper sulphate (Rapporteur FR)**

PT3

Meeting document: *WGIII2017\_EFF\_6-7*

*For discussion/agreement*

**Item 7 – Discussion of Union authorisations**

**7.1 Early WG discussion on UA applications for product families containing Iodine/PVP-Iodine**

Meeting document: *WGIII2017\_EFF\_7-1*

*For discussion/agreement*

**Item 8 – Technical and guidance related issues**

**8.1 Update on guidance development (ECHA)**

*For information*

**8.2 Revision of Volume II/B+C: PT19**

Meeting document: *WGIII2017\_EFF\_8-2*

*For discussion*

**8.3 Revision of Volume II/A**

Meeting document: *WGIII2017\_EFF\_8-3*

*For discussion/agreement*

**Item 9 – AOB**

**9.1 Other information & lessons learned (ECHA)**

SECR/WG members to inform and to reflect on the experience gained

*For information*

**2<sup>nd</sup> PT 18 Expert Group Meeting**  
*(Only relevant for assigned Expert Group members)*

**Chair: Heike Schimmelpfennig**

**Item 1 – Welcome and apologies**

**Item 2 – Agreement of the agenda**

*For agreement*

**Item 3 – Technical/guidance related issues**

**3.1 Follow up on open items of the 1<sup>st</sup> PT 18 EG meeting**

Meeting document: *PT18-EG2\_3-1*

*For discussion/agreement*

**3.2 Discussion of pre-identified items related to PT 18 - household and professional use**

Meeting document: *PT18-EG2\_3-2*

*For discussion/agreement*

**Item 4 – Closure and definition of follow-up actions**

**Environment Working Group**  
**Chair: Heike Schimmelpfennig**

**Item 1 – Welcome and apologies**

**Item 2 – Administrative issues**

**Item 3 – Agreement of the agenda**

*For agreement*

**Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

**Item 5 – Agreement of the draft minutes from WG-II-2017**

Meeting documents:

- *WGII2017\_ENV\_6-1\_Draft minutes*
- *WGII2017\_ENV\_6-2\_Draft minutes*
- *WGII2017\_ENV\_6-3\_Draft minutes*
- *WGII2017\_ENV\_General\_Draft minutes*

*For agreement*

**Item 6 – Discussion of active substances**

**6.1 Azoxystrobin (eCA UK)**

PT 07, 09, 10

Meeting document: *WGIII2017\_ENV\_6-1*

*For discussion/agreement*

**6.2 Chlorophene (eCA NO)**

PT 02, 03

Meeting document: *WGIII2017\_ENV\_6-2*

*For discussion/agreement*

**6.3 d-Allethrin (eCA DE)**

PT 18

Meeting document: *WGIII2017\_ENV\_6-3*

*For discussion/agreement*

**6.4 Esbiothrin (eCA DE)**

PT 18

Meeting document: *WGIII2017\_ENV\_6-4*

*For discussion/agreement*

**6.5 PHMB (1415; 4.7) (eCA FR)**

PT 01,02,04,05,06

Meeting document: *WGIII2017\_ENV\_6-5*

*For discussion/agreement*

## Item 7 – Discussion of Union authorisations

### 7.1 Early WG discussion on UA applications for product families containing Iodine/PVP-Iodine – WebEx

Meeting document: *WGIII2017\_ENV\_7-1*

*For discussion/agreement*

## Item 8 – Technical/guidance related issues (including AHEE members)

### 8.1 Update on guidance development and work of the AHEE (ECHA)

Meeting document: *WGIII2017\_ENV\_8-1*

*For information*

### 8.2 Proposal on exposure assessment of metabolites in the terrestrial compartment (DE)

Meeting document: *WGIII2017\_ENV\_8-2*

*For discussion/agreement*

### 8.3 Simplification of the exposure assessment (all PTs) for biocides (ECHA)

Meeting document: *WGIII2017\_ENV\_8-3*

*For discussion/agreement*

### 8.4 Applicability of the AHEE recommendation for PT 18 to PT 3 (ECHA)

Meeting document: *WGIII2017\_ENV\_8-4*

*For discussion/agreement*

### 8.5 Data requirements for precursors of in situ generated active substances (ECHA)

Meeting document: *WGIII2017\_ENV\_8-5*

*For agreement*

### 8.6 Ongoing developments related to PT 21 (NL, UK)

- a) Revision of the default value for the underwater surface area of pleasure craft (NL)
- b) Update/discussion on the development of harmonised scenarios for freshwater: pleasure craft and commercial ships (NL)
- c) Update on the situation for marine waters/marinas - feedback from the 70<sup>th</sup> CA meeting (UK)

Meeting document: *WGIII2017\_ENV\_8-6a-b*

*For information/discussion*

### 8.7 Definition of relevant impurities

Meeting document: *WGII2017\_ENV\_8-8*

*For discussion*

### 8.8 Specific items identified in the revision of Vol. IV Part B for WG follow up (ECHA)

Meeting document: *WGIII2017\_ENV\_8-9*

*For information*

### 8.9 Application of $F_{\text{wheaterside}}$ for PT 8 (groundwater assessment) and other PTs (DK/ECHA)

SECR to inform

*For information*

**8.10 How to use Fish Embryo Acute Toxicity (FET) Test Guideline (OECD 236) to fulfil information requirements under different regulation (ECHA)**

SECR to inform.

*For information*

**8.11 Outcome of the e-consultations initiated in Q1 2017 (ECHA)**

Meeting document: *WGIII2017\_ENV\_8-11*

*For information*

**Item 9 – AOB**

**9.1 Assessment of Endocrine Disruptors – update on status**

SECR to inform

*For information*

**9.2 Other information & lessons learned**

SECR/WG members to reflect on the experience gained

*For information*

oOo